Malaria - First global mapping of artemisinin resistance confirms definitively that resistance is confined to Southeast Asia and has not spread to sub-Saharan Africa

This article is over 10 years old

Published the 22 June 2016 Updated 14 October 2016

The first global mapping of artemisinin resistance (the KARMA study) has definitively confirmed that resistance to the main drug currently used in the treatment of Plasmodium falciparum malaria is for the moment confined to Southeast Asia and has not spread to sub–Saharan Africa.